Considering Triple Agents in Glucose Control - Application & Safety Considerations in 2026

Written By :  Dr. Nandita Mohan
Published On 2026-02-11 05:30 GMT   |   Update On 2026-02-11 05:42 GMT
Advertisement

In this episode of The Diabetes Wellness Forum, titled "Considering Triple Agents-Application & Safety Considerations in 2026," Dr Nandita Mohan from Medical Dialogues is in conversation with Dr. Om Lakhani, Dr Om Lakhani, Consultant Endocrinologist, AB Plus Hospital, Ahmedabad and Founder of Mellitus Healthcare LLP and technochrinology.com and Dr Ganpati, Professor, Department of Endocrinology, St. Johns Medical College, Bangalore to discuss critical aspects of diabetes care in 2026.

Advertisement

In uncontrolled type 2 diabetes (T2D), combination therapies are often essential to achieve meaningful glycemic control. Many patients, especially younger individuals with aggressively progressing disease, require triple-drug regimens to manage high glucose levels effectively. It is therefore crucial to understand how to initiate, sequence, and monitor triple therapy safely within the T2DM care continuum. Optimizing combinations based on patient profile, comorbidities, and treatment goals can significantly improve outcomes and reduce long-term complications.

During this episode, the experts address three key clinical questions:

1. When would you consider triple glucose-lowering drug therapy combination in your T2DM patients?

2. Based on your clinical experience, what will be the edge of Empagliflozin Sitagliptin Metformin triple combination in T2DM patients among other available triple FDCs in the T2DM care landscape? 

3. Based on your experience with Empagliflozin Sitagliptin, and Metformin as molecules you have used in different formulations over the years, what can be the beyond glycemic effects of this combination? 

4. What is your view on the safety of the Empagliflozin Sitagliptin Metformin triple combination? 

5. In which patient profiles would you consider Empagliflozin Sitagliptin Metformin FDC? 

#comments { display: none!important; } .responsive-video { position: relative; width: 100%; max-width: 100%; aspect-ratio: 16 / 9; /* Modern way, no padding hack */ } .responsive-video iframe { width: 100%; height: 100%; border: none; display: block; } @supports not (aspect-ratio: 16/9) { /* Fallback for browsers without aspect-ratio support */ .responsive-video { padding-top: 56.25%; height: 0; overflow: hidden; } .responsive-video iframe { position: absolute; top: 0; left: 0; } } .webinar_speakers .h3SmallScreen { display: none !important; }
Full View
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News